Roche pays $775M upfront for Cambridge biotech’s sophomore cancer drug
July 14, 2020 at 10:03 AM EDT
A Cambridge biotech is rebounding from an FDA rejection by signing a deal with drug giant Roche worth upwards of $1.7 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|